Pomalidomide Package Insert

Www.matulane.com
Created Date: 8/30/2011 1:26:04 PM ... Fetch Content

Submitted By: Eulena Horne, PharmD - Oncology
The use of pomalidomide in combination with existing agents such as bortezomib and dexamethasone (PVD) represents a triplet regimen which has demonstrated activity in patients with high risk disease. ... Read Full Source

Imnovid EPAR Summary Updated IA-01
Imnovid. 1. pomalidomide . This is a summary of the European public assessment report (EPAR) for Imnovid . It explains how the the package leaflet for Imnovid , including the appropriate precautions to be followed by healthcare professionals and patients. ... Return Doc

Reference ID: 4110010 - Velcade.com
Reference ID: 4110010. 4/38 2.3 Dose Modification Guidelines for VELCADE When Given in Combination with Melphalan and Prednisone . Prior to initiating any cycle of therapy with VELCADE in combination with melphalan and prednisone: ... Return Document

Celgene ist ein amerikanisches Pharmaunternehmen, das sich auf die Herstellung von Arzneimitteln gegen Krebserkrankungen und Krankheiten des Immunsystems spezialisiert hat.Der Sitz von Celgene befindet sich in Summit, New Jersey.Das sich als biopharmaceutical company beschreibende Unternehmen beschäftigt rund 7.500 Mitarbeiter bei einem Umsatz von 13,0 Mrd. ... Read Article

HIGHLIGHTS OF PRESCRIBING INFORMATION These ... - Folotyn
2 DOSAGE AND ADMINISTRATION 2.1 General Dosing and Administration 2.2 Monitoring and Dose Modifications 2.3 Special Handling Precautions 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Bone Marrow Suppression 5.2 Mucositis 5.3 Dermatologic Reactions 5.4 Tumor Lysis Syndrome 5.5 Hepatic Toxicity ... Get Content Here

MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, And Low ...
Pomalidomide (POM) has been approved in the US and EU1,2 – US: Patients (pts) who have received ≥ 2 prior treatments (Tx), including lenalidomide (LEN) and bortezomib (BORT) and have demonstrated disease ... Retrieve Document

POMALYST® (pomalidomide) Oral Capsule
Pomalidomide is an immunomodulatory agent with antineoplastic activity. In in vitro cellular assays, pomalidomide Package Insert. Revised by manufacturer 04/2015. Accessed 08-04-2015. Pomalyst. Package Insert. Revised by manufacturer 06/2016. ... View Doc

Submitted By: Eulena Horne, PharmD Date Of Request: April 8 ...
Pomalidomide 4 mg on Days 1-21, pembrolizumab 200 mg on Days 1 and 14 and dexamethasone 40 mg (20 mg if >70 years) on Days 1, 7, 14 and 21 were administered in 28day cycles. ... Read Full Source

EMPLICITI (elotuzumab) - Caremark
EMPLICITI (elotuzumab) Empliciti FEP Clinical Rationale RATIONALE FOR INCLUSION IN PA PROGRAM Background Empliciti is a monoclonal antibody that specifically targets the SLAMF7 protein. ... Return Document

HIGHLIGHTS OF PRESCRIBING INFORMATION These Highlights Do Not ...
Myfortic® (mycophenolic acid) is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. Myfortic is indicated for the prophylaxis of organ rejection in pediatric patients 5 years of age and older who are at least 6 months post kidney transplant. ... Retrieve Doc

A Phase 1b Study Of Durvalumab (MEDI4736) Alone Or In ...
A Phase 1b Study of Durvalumab (MEDI4736) Alone or in Combination With Pomalidomide With or Without Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Despite the availability of newer therapeutic options, outcomes for patients (pts) with multiple myeloma (MM) that is relapsed and/or refractory to current ... Retrieve Full Source

Safety Results Of A Phase 2 Multicenter, Open-Label Study Of ...
Safety Results of a Phase 2, Multicenter, Open-Label Study of Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment ... Return Document

Last Review Status/Date - Media.fepblue.org
In combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide Darzalex [package insert]. Horsham, PA: Janssen Biotech, Inc.; June 2017. ... Retrieve Content

Pomalidomide + Low-Dose Dexamethasone Following Second-Line ...
Is not cross-resistant with pomalidomide (POM)and that LEN-resistant myeloma cells remain sensitive to POM1,2 POM is a potent immunomodulatory agent with direct anti-tumor and immunoregulatory properties3 POM + low-dose dexamethasone (POM + LoDEX) is approved for the treatment (Tx) of relapsed/refractory multiple ... Access Full Source

POMALYST (pomalidomide) RATIONALE FOR INCLUSION IN PA PROGRAM
POMALYST (pomalidomide) RATIONALE FOR INCLUSION IN PA PROGRAM . Background . Pomalyst is an immunomodulatory agent used to treat patients with multiple myeloma who have not improved after being treated with other cancer drugs. Multiple myeloma is a form of blood cancer that primarily affects older adults and arises from plasma cells in the bone ... Fetch Full Source

Understanding POMALYST - Multiple Myeloma: International ...
(pomalidomide) capsules rst and largest organi[ation focusing speci cally on multiple myeloma The I.' s reach eYtends to more than members in countries enough to require an FDA-mandated “Boxed Warning” on the package insert. A Boxed Warning is the strictest warning put in the ... Content Retrieval